Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes: A Systematic Review and Meta-analysis of Individual Participant Data From 3 Randomized Clinical Trials
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The role of vitamin D in people who are at risk for type 2 diabetes remains unclear. PURPOSE: To evaluate whether administration of vitamin D decreases risk for diabetes among people with prediabetes. DATA SOURCES: PubMed, Embase, and ClinicalTrials.gov from database inception through 9 December 2022. STUDY SELECTION: Eligible trials that were specifically designed and conducted to test the effects of oral vitamin D versus placebo on new-onset diabetes in adults with prediabetes. DATA EXTRACTION: The primary outcome was time to event for new-onset diabetes. Secondary outcomes were regression to normal glucose regulation and adverse events. Prespecified analyses (both unadjusted and adjusted for key baseline variables) were conducted according to the intention-to-treat principle. DATA SYNTHESIS: Three randomized trials were included, which tested cholecalciferol, 20 000 IU (500 mcg) weekly; cholecalciferol, 4000 IU (100 mcg) daily; or eldecalcitol, 0.75 mcg daily, versus matching placebos. Trials were at low risk of bias. Vitamin D reduced risk for diabetes by 15% (hazard ratio, 0.85 [95% CI, 0.75 to 0.96]) in adjusted analyses, with a 3-year absolute risk reduction of 3.3% (CI, 0.6% to 6.0%). The effect of vitamin D did not differ in prespecified subgroups. Among participants assigned to the vitamin D group who maintained an intratrial mean serum 25-hydroxyvitamin D level of at least 125 nmol/L (≥50 ng/mL) compared with 50 to 74 nmol/L (20 to 29 ng/mL) during follow-up, cholecalciferol reduced risk for diabetes by 76% (hazard ratio, 0.24 [CI, 0.16 to 0.36]), with a 3-year absolute risk reduction of 18.1% (CI, 11.7% to 24.6%). Vitamin D increased the likelihood of regression to normal glucose regulation by 30% (rate ratio, 1.30 [CI, 1.16 to 1.46]). There was no evidence of difference in the rate ratios for adverse events (kidney stones: 1.17 [CI, 0.69 to 1.99]; hypercalcemia: 2.34 [CI, 0.83 to 6.66]; hypercalciuria: 1.65 [CI, 0.83 to 3.28]; death: 0.85 [CI, 0.31 to 2.36]). LIMITATIONS: Studies of people with prediabetes do not apply to the general population. Trials may not have been powered for safety outcomes. CONCLUSION: In adults with prediabetes, vitamin D was effective in decreasing risk for diabetes. PRIMARY FUNDING SOURCE: None. (PROSPERO: CRD42020163522).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Meta-analysis of individual participant data: rationale, conduct, and reporting
Riley, R. D., Lambert, P. C., & Abo-Zaid, G. (2010) · BMJ · doi:10.1136/bmj.c221 · Cited by 1,701
Get real in individual participant data (IPD) meta‐analysis: a review of the methodology
Debray, T. P. A., Moons, K. G. M., van Valkenhoef, G., Efthimiou, O., Hummel, N., Groenwold, R. H. H., Reitsma, J. B., & on behalf of the GetReal methods review group (2015) · Research Synthesis Methods · doi:10.1002/jrsm.1160 · Cited by 348
Finding What Works in Health Care: Standards for Systematic Reviews
Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, Board on Health Care Services, & Institute of Medicine (2011) · doi:10.17226/13059 · Cited by 289
Zhang, Y., Tan, H., Tang, J., Li, J., Chong, W., Hai, Y., Feng, Y., Lunsford, L. D., Xu, P., Jia, D., et al. (2020) · Diabetes Care · doi:10.2337/dc19-1708 · Cited by 195 · cited 3×
“Two meta-analyses of aggregate data from trials that assessed the effect of vitamin D on diabetes risk reported statistically significant relative risk reductions of 11% to 12% for new-onset diabetes with vitamin D (5, 6).”
BackgroundResultDawson-Hughes, B., Staten, M. A., Knowler, W. C., Nelson, J., Vickery, E. M., LeBlanc, E. S., Neff, L. M., Park, J., & Pittas, A. G. (2020) · Diabetes Care · doi:10.2337/dc20-1765 · Cited by 192
Self-citationAdjustment for Baseline Characteristics in Randomized Clinical Trials
Holmberg, M. J., & Andersen, L. W. (2022) · JAMA · doi:10.1001/jama.2022.21506 · Cited by 161 · cited 1×
“Additional models were adjusted for key variables that were preselected by the author group as the most relevant baseline characteristics associated with the primary outcome (age, gender, body mass index [BMI], race, and hemoglobin A1c level) (19, 20).”
MethodObesity Represses CYP2R1 , the Vitamin D 25‐Hydroxylase, in the Liver and Extrahepatic Tissues
Elkhwanky, M., Kummu, O., Piltonen, T. T., Laru, J., Morin‐Papunen, L., Mutikainen, M., Tavi, P., & Hakkola, J. (2020) · JBMR Plus · doi:10.1002/jbm4.10397 · Cited by 80
Cited by
Vitamin D for the prevention of disease: An Endocrine Society clinical practice guideline
Demay, M. B., Pittas, A. G., Bikle, D. D., Diab, D. L., Kiely, M. E., Lazaretti-Castro, M., Lips, P., Mitchell, D. M., Murad, M. H., Powers, S., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae290 · Cited by 639
Self-citationConsensus statement on vitamin D status assessment and supplementation: Whys, whens, and hows
Giustina, A., Bilezikian, J. P., Adler, R. A., Banfi, G., Bikle, D. D., Binkley, N. C., Bollerslev, J., Bouillon, R., Brandi, M. L., Casanueva, F. F., et al. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae009 · Cited by 392
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Eichorst, B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s005 · Cited by 305
Metadata
- Authors
- Pittas, A. G., Kawahara, T., Jorde, R., Dawson-Hughes, B., Vickery, E. M., Angellotti, E., Nelson, J., Trikalinos, T. A., & Balk, E. M.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2023-03
- Volume
- 176
- Issue
- 3
- Pages
- 355-363
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W4319303813
- Cited by
- 179
- References
- 8
- FWCI
- 29.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.